ライフサイエンスコーパス: hepatitis

1 n liver specimens from patients with chronic hepatitis.

2 ic NALD, but not in those with chronic viral hepatitis.

3 , such as autoimmune hepatitis and alcoholic hepatitis.

4 ic liver diseases and severe acute alcoholic hepatitis.

5 use of parenterally transmitted non-A, non-B hepatitis.

6 y); grade 3 or 4 immune-related AEs included hepatitis (0% and 13%, respectively) and colitis (0% and

7 g immunosuppressants; 3) using drugs or with hepatitis; 4) with diabetes mellitus; 5) consuming >1 al

8 ation efforts, including universal childhood hepatitis A (HepA) vaccination recommendations in 2006,

9 ting safe IDU practices, drug treatment, and hepatitis A and B vaccinations should be key components

10 her risk of infection with HAV and of severe hepatitis A disease outcomes compared with those not exp

11 We assessed risk factors for severe hepatitis A disease outcomes, including hospitalization

12 ce/ethnicity, health insurance coverage, and hepatitis A immunity by anti-HBc status.

13 nty of San Diego investigated an outbreak of hepatitis A infections primarily among people experienci

14 We measured the frequency of indications for hepatitis A vaccination according to Advisory Committee

15 patients recorded other ACIP indications for hepatitis A vaccination.

16 HPV 16/18 AS04-adjuvanted vaccine or control hepatitis A vaccine.

17 Hepatitis A virus (HAV) is a common infection that is tr

18 d States was surveyed for antibody titers to hepatitis A virus (HAV), measles virus (MeV), and cytome

19 (HepA) vaccination recommendations in 2006, hepatitis A virus (HAV)-associated outbreaks have increa

20 rticipate in cargo delivery from exosomes of hepatitis A virus (HAV)-infected cells (exo-HAV) by clat

21 ty in patients with acute alcohol-associated hepatitis (AAH).

22 expression was not affected by the degree of hepatitis activity, the stage of fibrosis, or by the dev

23 nfection but not for assessing the degree of hepatitis activity.

24 Alcoholic hepatitis (AH) is a severe manifestation of alcohol-asso

25 role of intrahepatic LCN2 in human alcoholic hepatitis (AH) with advanced fibrosis and portal hyperte

26 dysbiosis is associated with alcohol-related hepatitis (AH), with the mechanisms yet to be elucidated

27 arious liver pathologies, such as autoimmune hepatitis and alcoholic hepatitis.

28 asmosis manifesting with acute granulomatous hepatitis and cholestasis in a 48-year-old female with p

29 ymptomatic laboratory abnormalities (n = 4), hepatitis and colitis (n = 2).

30 aluated the number of patients who developed hepatitis and examined both demographics and inflammator

31 ced hyperinflammatory syndrome with necrotic hepatitis and in a nonalcoholic steatohepatitis model, r

32 Eighty CHC patients (17 chronic hepatitis, and 63 cirrhosis) were enrolled.

33 While increases in overdoses, viral hepatitis, and endocarditis associated with drug use hav

34 s, including alcoholic hepatitis, autoimmune hepatitis, and primary biliary cirrhosis.

35 various liver diseases, including alcoholic hepatitis, autoimmune hepatitis, and primary biliary cir

36 but overall population prevalence of chronic hepatitis B (CHB) infection remains high.

37 Chronic hepatitis B (CHB) is associated with a dysfunctional imm

38 lthy donors exposed to IFN-alpha and chronic hepatitis B (CHB) patients starting IFN-alpha therapy.

39 ctronic health record (EHR) alert on chronic hepatitis B (CHB) screening among at-risk Asian and Paci

40 ty and safety of a 3-antigen (S/preS1/preS2) hepatitis B (HepB) vaccine (3AV), to a single antigen va

41 acilitate the planning and evaluation of the hepatitis B and C control program in Malaysia.

42 As the country moves toward hepatitis B and C elimination, population-based estimate

43 es are necessary to understand the burden of hepatitis B and C for evidence-based policy-making.

44 All blood samples were tested for hepatitis B and C markers including hepatitis B surface

45 inery regulates host innate immunity against hepatitis B and C viral infections by inducing m(6)A mod

46 Hepatitis B and C virus-associated HCC became less commo

47 her chronic infections such as tuberculosis, hepatitis B and C, and HIV, as well as in autoimmunity a

48 study, including patients with cirrhosis and hepatitis B and C, from 2015 to 2017 who underwent treat

49 y and pathogenesis in the setting of chronic hepatitis B and C.

50 There are now effective treatments for hepatitis B and hepatitis C, and follow-up after effecti

51 segmental glomerulosclerosis (FSGS), LN and hepatitis B associated glomerulonephritis (HBV-GN) signi

52 Hepatitis B birth dose coverage of 90% is unlikely to be

53 ible intermediates on the assembly path from hepatitis B capsid protein dimers to the 120-dimer capsi

54 d poliomyelitis-Haemophilus influenza type b-hepatitis B combination vaccine were given at 2, 3, and

55 3 tests-hepatitis B surface antigen (HBsAg), hepatitis B core antibody (anti-HBc) total immunoglobuli

56 ng hepatitis B surface antigen (HBsAg), anti-hepatitis B core antibody (anti-HBc), antibodies against

57 prevalence of HBV infection) and antibody to hepatitis B core antigen (anti-HBc; prevalence of HBV ex

58 e ability of hepatitis B virus (HBV) RNA and hepatitis B core-related antigen (HBcrAg) as surrogates

59 Chronic hepatitis B develops more frequently in countries with h

60 NA) therapy; cohort B: 23 antibodies against hepatitis B e antigen (anti-HBe)-positive patients who s

61 Three cohorts of hepatitis B e antigen (HBeAg)-negative patients were stu

62 ed with HBV in vitro, causing a reduction of hepatitis B e antigen and specific loss of cells express

63 ltivariable analysis adjusting for age, sex, hepatitis B e antigen serostatus, and diabetes, the pres

64 outcomes, such as virologic suppression and hepatitis B e-antigen (HBeAg) or hepatitis B surface ant

65 rs (NRTI), drugs approved to treat HIV-1 and hepatitis B infections, also block inflammasome activati

66 Chronic hepatitis B is caused by prolonged infection with the he

67 ointestinal bleeding in persons with chronic hepatitis B or hepatitis C virus infection.

68 with men, 55.2% and 75.1% among persons with hepatitis B or hepatitis C, and 22.6% and 25.9% among th

69 four in the intravenous group (sepsis [n=2], hepatitis B reactivation [n=1], and Pneumocystis jirovec

70 sites in the United States and Canada of the Hepatitis B Research Network.

71 mous separation of hepatitis B viral DNA and hepatitis B surface antigen (HBsAg) concentrations occur

72 Hepatitis D virus (HDV) requires hepatitis B surface antigen (HBsAg) for its assembly and

73 Secondary outcomes were reductions in hepatitis B surface antigen (HBsAg) in control and exper

74 API patients who had not yet completed hepatitis B surface antigen (HBsAg) testing were identif

75 sted for hepatitis B and C markers including hepatitis B surface antigen (HBsAg), anti-hepatitis B co

76 therapy should be tested for HBV by 3 tests-hepatitis B surface antigen (HBsAg), hepatitis B core an

77 s of adults that reported prevalence of both hepatitis B surface antigen (HBsAg; prevalence of HBV in

78 n of 4.6 years, the cumulative incidences of hepatitis B surface antigen and HBeAg seroclearance were

79 ression and hepatitis B e-antigen (HBeAg) or hepatitis B surface antigen loss or seroconversion; the

80 HBV infection (hepatitis B surface antigen) was diagnosed with serologi

81 oteins of three sizes, collectively known as hepatitis B surface antigen, and adopts multiple conform

82 immunoglobulin (Ig) or IgG, and antibody to hepatitis B surface antigen-but anticancer therapy shoul

83 Participants were anti-HIV/hepatitis B surface antigen-positive adults from eight c

84 is mathematical modelling study of perinatal hepatitis B transmission and disease progression, we est

85 A hepatitis B vaccine was administered to 66 young Latvian

86 he highest levels of antibody titers against hepatitis B vaccine.

87 A dichotomous separation of hepatitis B viral DNA and hepatitis B surface antigen (H

88 pe similarity driving immune response in the hepatitis B virally infected liver cancer TCGA cohort, a

89 New hepatitis B virions released from infected hepatocytes a

90 er extensive mixed tailing in transcripts of hepatitis B virus (HBV) and human cytomegalovirus (HCMV)

91 ed viruses such as Epstein-Barr virus (EBV), hepatitis B virus (HBV) and human papilloma virus (HPV;

92 Patients co-infected with hepatitis B virus (HBV) and the human immunodeficiency v

93 tion efforts, their lack of activity against hepatitis B virus (HBV) could limit their global impact,

94 Hepatitis B virus (HBV) covalently closed circular (ccc)

95 The biosynthesis of hepatitis B virus (HBV) covalently closed circular DNA (

96 The paucity of hepatitis B virus (HBV) DNA measurement in low-/middle-i

97 r DNA (cccDNA) is the persistent form of the hepatitis B virus (HBV) genome in viral infection and an

98 Rare individuals can naturally clear chronic hepatitis B virus (HBV) infection and acquire protection

99 Development Goals (SDGs) for elimination of hepatitis B virus (HBV) infection set ambitious targets

100 infection (LTBI), 63.5% were susceptible to hepatitis B virus (HBV) infection, and 31.0% had at leas

101 hough there is no effective cure for chronic hepatitis B virus (HBV) infection, antibodies are protec

102 ing age in the United States, but changes in hepatitis B virus (HBV) infections have not been studied

103 ra DNA (vh-DNA), generated from junctions of hepatitis B virus (HBV) integration in the HCC chromosom

104 Hepatitis B virus (HBV) is a leading cause of liver dise

105 Its occurrence as a satellite virus of hepatitis B virus (HBV) is a singular case in animal vir

106 Hepatitis B virus (HBV) is an important but difficult to

107 h, particularly in sub-Saharan Africa, where hepatitis B virus (HBV) is an important risk factor.

108 Hepatitis B virus (HBV) is the leading cause of hepatoce

109 Hepatitis B virus (HBV) is the major causative factor of

110 esponse and Organ failure) for patients with Hepatitis B Virus (HBV) related acute-on-chronic liver f

111 Hepatitis B virus (HBV) remains a major global health pr

112 79), a capsid assembly modulator that blocks hepatitis B virus (HBV) replication, was well tolerated

113 We have evaluated the ability of hepatitis B virus (HBV) RNA and hepatitis B core-related

114 B is caused by prolonged infection with the hepatitis B virus (HBV), which can substantially increas

115 to exclude and confirm advanced fibrosis in hepatitis B virus (HBV)-human immunodeficiency virus (HI

116 he US are living with chronic infection with hepatitis B virus (HBV).

117 incidence/1000 patient-years was 49.3 among hepatitis B virus (HBV)/hepatitis C virus (HCV) coinfect

118 confirm upregulation of Gal-9 on T cells in hepatitis B virus and HPV infections.

119 ed a prolonged suppression of human and duck hepatitis B virus cccDNA transcription, which is associa

120 ned (1:1) HLA-B*5701-negative adults without hepatitis B virus co-infection to receive coformulated b

121 those with a human immunodeficiency virus or hepatitis B virus coinfection, and those treated with bo

122 age, gender, smoking status, hepatitis C and hepatitis B virus coinfection, group of exposure, nadir

123 sity control, immunizing populations against hepatitis B virus infection, and screening for colorecta

124 that can affect replication of retroviruses, hepatitis B virus, and hepatitis C virus (HCV).

125 rus (WHV), a hepadnavirus closely related to hepatitis B virus.

126 ir measurement during the natural history of hepatitis B, and on treatment with current and new agent

127 nisation for diphtheria, tetanus, pertussis, hepatitis B, Haemophilus influenzae type b, Streptococcu

128 uring the exam, including tuberculosis (TB), hepatitis B, hepatitis C, malaria, strongyloidiasis, sch

129 chemotherapy diphtheria, tetanus, pertussis, hepatitis B, polio, and Haemophilus influenzae type b (D

130 o multivariate analysis were the etiology of hepatitis B, the stage of Barcelona Clinic Liver Cancer

131 the natural history and treatment of chronic hepatitis B.

132 strategy for the functional cure of chronic hepatitis B.

133 a comeback, potentially increasing risk for hepatitis B.

134 hlight mother-to-child transmission of viral hepatitis, both management and public health implication

135 , followed by cryptogenic cirrhosis (14.5%), hepatitis C (13.4%), and non-alcoholic fatty liver disea

136 d the highest rate of endocarditis (16%) and hepatitis C (44%).

137 8.5%; RR, 3.7 [95% CI, 3.1-4.4]), those with hepatitis C (54.7% vs 6.4%; RR, 8.5 [95% CI, 6.5-11.3]),

138 nt of human immunodeficiency virus (HIV) and hepatitis C (HCV) coinfected patients with advanced live

139 A hepatitis C (HCV) cure is associated with changes in lip

140 possible links between DO and autoimmunity, Hepatitis C (HCV) infection, and cancer, but the mechani

141 of these programs on the rate of new HIV and Hepatitis C (HCV) infections remains unknown as high mor

142 t of removing fibrosis stage restrictions on hepatitis C (HCV) treatment initiation rates among peopl

143 adjustment for age, gender, smoking status, hepatitis C and hepatitis B virus coinfection, group of

144 ncidence rates of participants in the German hepatitis C cohort (GECCO) and compared our data to prev

145 in treatment-naive participants in the Swiss Hepatitis C Cohort Study.

146 el of HCV disease progression and treatment (hepatitis C cost-effectiveness model: HEP-CE).

147 try of Georgia embarked on the world's first hepatitis C elimination program.

148 Georgia's hepatitis C elimination programme has achieved substanti

149 n screening and treatment to achieve the WHO hepatitis C elimination target of an 80% reduction in in

150 estimated 150 000 adults living with chronic hepatitis C in Georgia, 52 856 (35.1%) were diagnosed, 4

151 000) treatments started annually, decreasing hepatitis C incidence by 26.5% (22.5-30.7) over 2018-30.

152 up screening and treatment to reduce global hepatitis C incidence by 80% by 2030, but little is know

153 Decreasing hepatitis C incidence by 80% is estimated to require a d

154 timated in terms of the relative decrease in hepatitis C incidence, prevalence, and mortality relativ

155 HIV acquisition (aOR, 2.2; 95% CI, 1.3-3.9), hepatitis C infection (aOR, 1.9; 95% CI, 1.1-3.4), black

156 substance use treatment or primary care with hepatitis C prescribers.

157 60-2015 (including population growth) and to hepatitis C seroprevalence data from a national survey i

158 ys among people who inject drugs (PWID), and hepatitis C seroprevalence trends among blood donors.

159 The effectiveness of hepatitis C testing and linkage-to-care (LTC) is poorly

160 HCV/HIV co-infected individuals to Eliminate Hepatitis C transmission) was an implementation trial pr

161 tion-level effectiveness of these oral DAAs, hepatitis C treatment by a wide range of providers in di

162 ative scenarios for scaling up screening and hepatitis C treatment in 2018-30.

163 eported in liver transplantation and chronic hepatitis C treatment outcomes.

164 pangenotypic regimen suitable for mass-scale hepatitis C treatment, especially in resource-limited co

165 epatitis C with cost data on diagnostics and hepatitis C treatment.

166 core antibody (anti-HBc), antibodies against hepatitis C virus (anti-HCV).

167 Hepatitis C virus (HCV) and alcohol use are patient risk

168 obtained from unrelated cases infected with hepatitis C virus (HCV) and compared its performance wit

169 eath and tumoral recurrence in patients with hepatitis C virus (HCV) and hepatocellular carcinoma (HC

170 Patients were tested for HBV, hepatitis C virus (HCV) and HIV.

171 e who inject drugs have a high prevalence of hepatitis C virus (HCV) and significant disease associat

172 Here, we show that hepatitis C virus (HCV) co-opts the host protein CypA to

173 years was 49.3 among hepatitis B virus (HBV)/hepatitis C virus (HCV) coinfected and 18.2 among HCV mo

174 mation in human immunodeficiency virus (HIV)/hepatitis C virus (HCV) coinfection increases cognitive

175 ose, human immunodeficiency virus (HIV), and hepatitis C virus (HCV) due to injection drug use (IDU)

176 iological function for the p7 viroporin from hepatitis C virus (HCV) during virus entry, but also ena

177 The World Health Organization's (WHO) hepatitis C virus (HCV) elimination target of an 80% red

178 of-life (HRQL) improvements in patients with hepatitis C virus (HCV) has been generally accepted.

179 k of immunocompetent small animal models for hepatitis C virus (HCV) has greatly hindered the develop

180 g for human immunodeficiency virus (HIV) and hepatitis C virus (HCV) infection among persons who inje

181 lth Organization has set a goal to eliminate hepatitis C virus (HCV) infection as public health threa

182 al natural killer (NK) cell responses during hepatitis C virus (HCV) infection can be restored after

183 Since 2002, a global epidemic of acute hepatitis C virus (HCV) infection has been noted in men

184 Liver disease as a result of chronic hepatitis C virus (HCV) infection is a global problem.

185 BACKGROUNDChronic hepatitis C virus (HCV) infection is characterized by a

186 Chronic hepatitis C virus (HCV) infection is characterized by ac

187 Hepatitis C virus (HCV) infection is common among people

188 Hepatitis C virus (HCV) infection is highly prevalent am

189 Chronic hepatitis C virus (HCV) infection is one of the major ca

190 Hepatitis C virus (HCV) infection is the main cause of h

191 Hepatitis C virus (HCV) infection promotes hepatocyte gr

192 erum aspartate aminotransferase (AST) value, Hepatitis C virus (HCV) infection, alcohol abuse, CD4/CD

193 abase was used to identify adults with NASH, hepatitis C virus (HCV) infection, and alcohol-related l

194 ldren under 12 years of age who have chronic hepatitis C virus (HCV) infection, there are currently n

195 CD4+ T cell failure is a hallmark of chronic hepatitis C virus (HCV) infection.

196 direct-acting antiviral treatment (DAA) for hepatitis C virus (HCV) infection.

197 Hepatitis C virus (HCV) is a blood borne pathogen mostly

198 The E2 glycoprotein of hepatitis C virus (HCV) is the major target of broadly n

199 rals (DAAs) has transformed the landscape of hepatitis C virus (HCV) management.

200 Hepatitis C virus (HCV) may increase pulmonary hypertens

201 The discovery of a pan-genotypic hepatitis C virus (HCV) NS3/4A protease inhibitor based

202 We conducted a retrospective cohort study of hepatitis C virus (HCV) patients who achieved SVR with D

203 ors, and social determinants associated with hepatitis C virus (HCV) reinfection following DAA therap

204 Hepatitis C virus (HCV) remains endemic among people who

205 Clearance of hepatitis C virus (HCV) results in rapid changes in meta

206 We analyzed post-treatment hepatitis C virus (HCV) RNA levels from 330 subjects who

207 S Preventive Services Task Force (USPSTF) of hepatitis C virus (HCV) screening found interferon-based

208 Hepatitis C virus (HCV) screening is critical to HCV eli

209 e NS5A inhibitors underpin hugely successful hepatitis C virus (HCV) therapy.

210 Currently, the only approved hepatitis C virus (HCV) treatment for children aged <12

211 he effects of interferon-based therapies for hepatitis C virus (HCV) upon the risk of diabetes are co

212 Some people living with hepatitis C virus (HCV) with sustained virological respo

213 rary 2019, 532 individuals were screened for hepatitis C virus (HCV), 180 tested HCV antibody positiv

214 the existence of established treatments for hepatitis C virus (HCV), more effective means of prevent

215 By deciphering mechanistic aspects of hepatitis C virus (HCV)-host interactions, one could dis

216 milarity to eIF3 recognizing motifs found in hepatitis C virus (HCV)-like IRESs, suggesting mechanist

217 Risk factors for DGF in the hepatitis C virus (HCV)-negative recipient population in

218 Outcomes following hepatitis C virus (HCV)-viremic heart transplantation in

219 tion of retroviruses, hepatitis B virus, and hepatitis C virus (HCV).

220 ika virus (ZIKV), West Nile virus (WNV), and hepatitis C virus (HCV).

221 is of human immunodeficiency virus (HIV) and hepatitis C virus .

222 responding to chronic viral infections (HIV, hepatitis C virus [HCV], Epstein-Barr virus [EBV], and c

223 The WHO elimination strategy for hepatitis C virus advocates scaling up screening and tre

224 targets of interest (Plasmodium falciparum, Hepatitis C virus and T-cells) to demonstrate the value

225 ses, decompensated cirrhosis, cirrhosis, and hepatitis C virus compared to patients with chronic HBV.

226 Hepatitis C virus cure in coinfection brings monocyte ac

227 nstable housing, previous incarceration, and hepatitis C virus exposure.

228 l lines as well as antiviral effects against hepatitis C virus in the replicon assay.

229 Hepatitis C virus infection (OR, 15.84; 95% confidence i

230 ansfusions throughout her life, leading to a hepatitis C virus infection (which was treated, achievin

231 Eliminating the burden of disease caused by hepatitis C virus infection is proving difficult, despit

232 Approximately 29.6% prevalence of Hepatitis C virus infection observed among inmates studi

233 Poverty, injection drug use, and hepatitis C virus infection were also associated.

234 e II diabetes (T2D) may worsen the course of hepatitis C virus infection with a greater risk of liver

235 eding in persons with chronic hepatitis B or hepatitis C virus infection.

236 emic has been associated with an increase in hepatitis C virus infections among women of childbearing

237 e to an effective vaccine for HCV.IMPORTANCE Hepatitis C virus infects approximately 1% of the world'

238 even when under antiretroviral therapy), and hepatitis C virus or those of mice with lymphocytic chor

239 allosteric inhibitors have been reported for hepatitis C virus RdRp, few have been described for DENV

240 Hepatitis C virus SVR decreased monocyte interferon gene

241 We adapted a previous model of hepatitis C virus transmission, treatment, and disease p

242 coronavirus, human immunodeficiency virus 1, hepatitis C virus, and Japanese encephalitis virus.

243 , e.g., SARS-CoV-2, influenza, dengue fever, hepatitis C virus, HIV, rotavirus and Zika virus.

244 viral agents, there has been a rapid rise in hepatitis C virus-infected (HCV+) heart transplantation.

245 proteins of human immunodeficiency virus and hepatitis C virus.

246 ridae family, including Zika, West Nile, and hepatitis C viruses.

247 Those reactive for hepatitis C were further tested for HCV RNA genotyping.

248 o incorporate a detailed cascade of care for hepatitis C with cost data on diagnostics and hepatitis

249 latform to model specific virus types (e.g., hepatitis C) and add additional cellular mechanisms (tis

250 and 75.1% among persons with hepatitis B or hepatitis C, and 22.6% and 25.9% among the immunization

251 now effective treatments for hepatitis B and hepatitis C, and follow-up after effective treatment sho

252 m, including tuberculosis (TB), hepatitis B, hepatitis C, malaria, strongyloidiasis, schistosomiasis,

253 -up, which has reduced the burden of chronic hepatitis C.

254 g Interferon-alpha (IFN-alpha) treatment for Hepatitis-C develop major depressive disorder (MDD).

255 Hepatitis D virus (HDV) requires hepatitis B surface ant

256 The paucity of data regarding the extent of hepatitis delta virus (HDV) associated health care burde

257 Chronic hepatitis delta virus (HDV) infection causes severe live

258 pproximately 20 million are co-infected with hepatitis delta virus (HDV).

259 Two classes of pathogenic RNAs (hepatitis delta virus in animals and viroids in plants)

260 High hepatitis E (HEV) seroprevalence has been reported in th

261 s currently recommended for treating chronic hepatitis E virus (HEV) infection.

262 urther, we show that enterically transmitted hepatitis E virus (HEV) progeny particles are secreted b

263 tudy of Hecolin(R), the licensed vaccine for hepatitis E virus (HEV).

264 ange of diseases in mice and rats, including hepatitis, enteritis, respiratory diseases, and encephal

265 were baseline clinical liver disease, viral hepatitis, ethanol intake >50 g/day, and current abstain

266 e clinical setting of severe acute alcoholic hepatitis, further studies are needed for the identifica

267 Syphilitic hepatitis generally is mild clinical condition and is ch

268 " under the revised International Autoimmune Hepatitis Group (IAIHG) scoring system.

269 Patients with alcoholic hepatitis had significantly higher ASCA levels compared

270 ionwide study of patients with chronic viral hepatitis in Sweden, use of low-dose aspirin was associa

271 le of the intestinal microbiome in alcoholic hepatitis is not established.

272 o having diabetes, four of five patients had hepatitis-like episodes in childhood.

273 the major causative factor of chronic viral hepatitis, liver cirrhosis, and hepatocellular carcinoma

274 crobiome in patients with moderate alcoholic hepatitis (MAH) or severe alcoholic hepatitis (SAH) was

275 who underwent liver biopsy for chronic viral hepatitis (n=19) or other chronic non-alcoholic liver di

276 We studied 13,298 viral hepatitis negative adults who fasted at least 4 hours us

277 None had prior or current viral hepatitis or excessive alcohol intake.

278 th HIV mono-infection, without chronic viral hepatitis or other known causes of chronic liver disease

279 e region 1 of HCV were analyzed using Global Hepatitis Outbreak and Surveillance Technology.

280 biota in a cohort of patients with alcoholic hepatitis, patients with alcohol use disorder, and nonal

281 Only hepatitis predicted conversion to schizophrenia after su

282 ccinations should be key components of viral hepatitis prevention.

283 tients in the atezolizumab group (autoimmune hepatitis related to atezolizumab [n=1] and septic shock

284 lcoholic hepatitis (MAH) or severe alcoholic hepatitis (SAH) was compared with healthy controls (HCs)

285 liver specimens from patients with alcoholic hepatitis, the AR up-regulation and elevated AR metaboli

286 ever, in the subgroup of patients with viral hepatitis these correlations were no longer significant.

287 durvalumab group (acute hepatic failure and hepatitis), two (1%) patients in the durvalumab plus tre

288 ice with the neurotropic JHM strain of mouse hepatitis virus (JHMV) (a member of the Coronaviridae fa

289 Mouse hepatitis virus (MHV) is a murine betacoronavirus (m-CoV

290 hR is activated in cells infected with mouse hepatitis virus (MHV), a coronavirus (CoV), and contribu

291 nfected with a prototypic coronavirus, mouse hepatitis virus (MHV), resulting in the expression of se

292 Mouse hepatitis virus (MHV; murine coronavirus) causes meningo

293 odchucks chronically infected with woodchuck hepatitis virus (WHV), a hepadnavirus closely related to

294 Using a neurotropic mouse hepatitis virus encephalomyelitis model, this study demo

295 irus hemagglutinin and in variants of murine hepatitis virus, a coronavirus.

296 ere highly susceptible to a murine CoV-mouse hepatitis virus.

297 Alcoholic hepatitis was associated with a distinct microbiome sign

298 Hepatitis was present in 19 subjects (43%) and was assoc

299 omas (HCCs) develop in patients with chronic hepatitis, which creates a microenvironment for the grow

300 nths of enrollment and either acute clinical hepatitis within the past 12 months (symptomatic serocon